![Phillip Dennis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 137 207 $ al 31/08/2026
Dr. Phillip Dennis is a Chief Medical Officer at NovaBridge Biosciences and a Member at American Society for Clinical Investigation.
He received his graduate degree from New York University School of Medicine and a doctorate degree from New York University School of Medicine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NOVABRIDGE BIOSCIENCES 0,09 % | 18/09/2026 | 173.427 ( 0,09 % ) | 137 207 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NOVABRIDGE BIOSCIENCES | Director Técnico/Científico/I+D | 17/06/2024 |
American Society for Clinical Investigation
 American Society for Clinical Investigation BiotechnologyHealth Technology Provides clinical investigation services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
American Society for Clinical Investigation
American Society for Clinical Investigation BiotechnologyHealth Technology Provides clinical investigation services | Health Technology |
New York University School of Medicine
 New York University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
I-Mab
 I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
